A group of top pharmaceutical companies have teamed up to develop diagnostic tests to identify patients at risk of dangerous adverse drug reactions. The Serious Adverse Events Consortium (SAEC), which includes Abbott, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche, sanofi-aventis and Wyeth, will begin by searching for genetic links to severe liver toxicity and the dangerous skin condition known as Stevens-Johnson syndrome. (11/20/2007) |
As David Impey, consultant for BigBear Communications points out, the environments for direct to consumer advertising (DTCA) in Europe and in the United States are very different. (11/20/2007) |
Just how important is it to understand how much you’re spending on sales and marketing and where exactly that money is going? According to Stewart Adkins, Director of Stewart Adkins Advisors, Ltd., nothing could be more important right now. (11/20/2007) |
At a recent webinar co-sponsored by eyeforpharma and TNS Healthcare, panelists spoke on the new environment in pharma sales and the best ways to meet the challenges of reduced physician access and, in many places, increasing budgetary concerns. (11/6/2007) |
In a recent webinar co-sponsored by eyeforpharma and TNS Healthcare, panelists Greg Ciarelli of Boehringer Ingelheim and Brad Fackler of Sucampo Pharmaceuticals spoke about changes in pharma sales and how best to leverage sales and marketing forces in this new, more customer-centered sales environment. (11/6/2007) |
| See More News from eyeforpharma.com ... |